Carl Zeiss Meditec’s shares plummeted by approximately 13% to €41.68 following its quarterly earnings report, despite posting a 7.6% revenue increase to €1.6 billion over nine months. The decline reflects investor disappointment over weak organic growth, which stood at just 1.1% after excluding acquisitions and currency effects. The company faced significant headwinds, including new U.S. tariffs and unfavorable exchange rates, which slashed pre-tax profits by 26% to €126.7 million. While adjusted earnings per share dipped from €1.35 to €1.24, the operational business showed resilience, with EBITA rising 3.1% to €175.4 million.
Mixed Performance Across Segments
The medical technology firm reported a stark divide between its segments: Microsurgery grew by 10%, while the larger Ophthalmology division stagnated. Geographically, Europe and Asia-Pacific saw gains, but the Americas recorded a decline. Despite a 23.3% surge in orders, analysts remain cautious, citing risks to the full-year outlook. Management reaffirmed its forecast, targeting moderate revenue growth and stable EBITA margins, though further currency volatility could pose challenges. Investors, however, remain wary, as the sharp stock drop underscores concerns over profitability.
Ad
Carl Zeiss Meditec Stock: Buy or Sell?! New Carl Zeiss Meditec Analysis from February 6 delivers the answer:
The latest Carl Zeiss Meditec figures speak for themselves: Urgent action needed for Carl Zeiss Meditec investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 6.
Carl Zeiss Meditec: Buy or sell? Read more here...
